Loading
NASDAQHealthcareMedical - Specialties
Latest quote
$11.74
+$0.27 · +2.35%
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Regular session
$11.74
+$0.27 · +2.35%
Regular session · ET · Market data may be delayed.
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Day range
Current $11.74
52-week range
Current $11.74
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
60
Mixed
Risk
38
Moderate Risk
Momentum
53
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Day range
Current $11.74
52-week range
Current $11.74
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 52.23M USD | 41.02M USD | 31.79M USD | 27.18M USD | 29.66M USD |
| Cost of goods sold | 12.84M USD | 10.44M USD | 8.31M USD | 7.13M USD | 6.6M USD |
| Gross profit | 39.39M USD | 30.58M USD | 23.48M USD | 20.05M USD | 23.06M USD |
| Research and development | 9.6M USD | 7.19M USD | 6.67M USD | 7.68M USD | 6.39M USD |
| Selling, general, and administrative | 25.46M USD | 22M USD | 21.64M USD | 25.05M USD | 21.66M USD |
| Operating expenses | 35.06M USD | 29.19M USD | 28.44M USD | 32.73M USD | 28.06M USD |
| Interest income | 5.64M USD | 2.48M USD | 2.17M USD | 1.11M USD | 225K USD |
| Interest expense | 2.23M USD | 1.36M USD | 298K USD | 68K USD | 141K USD |
| Depreciation and amortization | 1.54M USD | 1.77M USD | 1.34M USD | 1.53M USD | 1.69M USD |
| Operating income | 4.32M USD | 1.39M USD | −4.96M USD | −12.68M USD | −5M USD |
| Net income | 7.63M USD | 2.92M USD | −4.2M USD | −13.35M USD | −6.46M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$19.50
66.10% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 4, 2026 | 2:1 | — | — |
Effective Mar 4, 2026
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Israel Innovative Technology ETFIZRL1.68M1.29%136.9M USD0.49%$28.11+0.72%
Amplify BlueStar Israel Technology ETFITEQ830.26K0.77%107.15M USD0.75%$61.24260.00%
ActivePassive International Equity ETFAPIE201.21K0.02%1.13B USD0.45%$38.310.00%
Even Herd Long Short ETFEHLS174.18K0.30%58.83M USD2.62%$25.36-0.08%
iShares Neuroscience and Healthcare ETFIBRN41.03K0.65%6.37M USD0.47%$31.39280.00%
Defiance Autism Impact ETFASD29.06K2.22%1.32M USD0.79%$26.445+0.40%ARK Israel Innovative Technology ETFIZRLAmplify BlueStar Israel Technology ETFITEQActivePassive International Equity ETFAPIEEven Herd Long Short ETFEHLSiShares Neuroscience and Healthcare ETFIBRNDefiance Autism Impact ETFASDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
